AG˹ٷ

STOCK TITAN

[8-K] Ensysce Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Ensysce Biosciences reported that it furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is included as Exhibit 99.1 and the filing also references the company's Inline XBRL cover page. The disclosure clarifies that the press release and related information are furnished, not "filed," and therefore are not incorporated by reference into other securities filings. The report contains a standard forward-looking statements caution describing assumptions, risks, and uncertainties that could cause actual results to differ from expectations. The filing confirms the company's common stock trades under the symbol ENSC on the Nasdaq exchange.

Ensysce Biosciences ha comunicato di aver fornito un comunicato stampa con i risultati finanziari per il trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 e la presentazione fa riferimento anche alla pagina di copertina Inline XBRL della società. Si precisa che il comunicato e le informazioni correlate sono 'furnished' e non 'filed', perciò non vengono incorporati per riferimento in altre comunicazioni sui titoli. Il rapporto contiene l'avvertenza standard sulle dichiarazioni prospettiche, che descrive ipotesi, rischi e incertezze che potrebbero far sì che i risultati effettivi differiscano dalle aspettative. La presentazione conferma che le azioni ordinarie della società sono negoziate con il simbolo ENSC sul mercato Nasdaq.

Ensysce Biosciences informó que suministró un comunicado de prensa con sus resultados financieros correspondientes al trimestre fiscal concluido el 30 de junio de 2025. El comunicado se incluye como Exhibit 99.1 y la presentación también hace referencia a la portada Inline XBRL de la compañía. Se aclara que el comunicado y la información relacionada son 'furnished', no 'filed', por lo que no se incorporan por referencia en otros documentos de valores. El informe incluye la advertencia estándar sobre declaraciones prospectivas que describe las suposiciones, riesgos e incertidumbres que podrían provocar que los resultados reales difieran de las expectativas. La presentación confirma que las acciones ordinarias de la compañía cotizan en Nasdaq bajo el símbolo ENSC.

Ensysce Biosciences� 2025� 6� 30일로 종료� 회계 분기� 대� 재무 결과� 발표� 보도자료� 제공했다� 보고했습니다. 해당 보도자료� Exhibit 99.1� 첨부되어 있으�, 제출서류에는 회사� Inline XBRL 표지 페이지� 언급되어 있습니다. 보도자료 � 관� 정보� 'furnished'이고 'filed'가 아니�, 따라� 다른 증권 제출서류� 참조� 통합되지 않는다고 명확� 밝힙니다. 보고서에� 실제 결과가 예상� 달라� � 있는 가�, 위험 � 불확실성� 설명하는 표준적인 전향� 진술 경고문이 포함되어 있습니다. 제출서는 회사� 보통주가 Nasdaq에서 ENSC라는 심볼� 거래되고 있음� 확인합니�.

Ensysce Biosciences a déclaré avoir fourni un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et le dépôt fait également référence à la page de couverture Inline XBRL de la société. Il est précisé que le communiqué et les informations connexes sont 'furnished' et non 'filed', et ne sont donc pas incorporés par renvoi dans d'autres documents relatifs aux titres. Le rapport contient la mise en garde standard relative aux déclarations prospectives, décrivant les hypothèses, les risques et les incertitudes susceptibles d'entraîner un écart entre les résultats réels et les attentes. Le dépôt confirme que les actions ordinaires de la société sont négociées sur le Nasdaq sous le symbole ENSC.

Ensysce Biosciences gab bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 beendete Geschäftsquartal übermittelt hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die Einreichung verweist zudem auf die Inline-XBRL-Titelseite des Unternehmens. Es wird klargestellt, dass die Pressemitteilung und die zugehörigen Informationen 'furnished' und nicht 'filed' sind und daher nicht durch Verweis in andere Wertpapierunterlagen einbezogen werden. Der Bericht enthält die übliche Warnung zu zukunftsgerichteten Aussagen, die Annahmen, Risiken und Unsicherheiten beschreibt, die dazu führen können, dass die tatsächlichen Ergebnisse von den Erwartungen abweichen. Die Einreichung bestätigt, dass die Stammaktien des Unternehmens an der Nasdaq unter dem Symbol ENSC gehandelt werden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine disclosure; press release announces Q2 results but this 8-K furnishes the release without financial details, limiting immediate analytical value.

The filing notifies investors that Ensysce furnished a press release covering results for the quarter ended June 30, 2025. Because the 8-K itself does not include financial figures, analysts must review Exhibit 99.1 to assess revenue, profitability, cash position, or guidance. The filing’s statement that the release is "furnished, not filed" is a legal distinction that limits incorporation by reference into other SEC filings; it does not change the commercial information disclosed. The forward-looking statements caution is standard and signals management may include projections or expectations in the press release.

TL;DR: Governance and disclosure procedures appear routine; the company timely furnished a press release and included required exhibits and XBRL cover page.

The 8-K documents compliance with disclosure obligations by furnishing a press release as Exhibit 99.1 and providing an Inline XBRL cover page (Exhibit 104). The explicit language that the release is furnished, not filed, reflects standard practice to avoid automatic incorporation into other securities filings. The inclusion of a comprehensive forward-looking statements paragraph helps manage legal exposure but does not substitute for audited or detailed financial statements, which investors should obtain by reviewing the attached press release and subsequent filings.

Ensysce Biosciences ha comunicato di aver fornito un comunicato stampa con i risultati finanziari per il trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 e la presentazione fa riferimento anche alla pagina di copertina Inline XBRL della società. Si precisa che il comunicato e le informazioni correlate sono 'furnished' e non 'filed', perciò non vengono incorporati per riferimento in altre comunicazioni sui titoli. Il rapporto contiene l'avvertenza standard sulle dichiarazioni prospettiche, che descrive ipotesi, rischi e incertezze che potrebbero far sì che i risultati effettivi differiscano dalle aspettative. La presentazione conferma che le azioni ordinarie della società sono negoziate con il simbolo ENSC sul mercato Nasdaq.

Ensysce Biosciences informó que suministró un comunicado de prensa con sus resultados financieros correspondientes al trimestre fiscal concluido el 30 de junio de 2025. El comunicado se incluye como Exhibit 99.1 y la presentación también hace referencia a la portada Inline XBRL de la compañía. Se aclara que el comunicado y la información relacionada son 'furnished', no 'filed', por lo que no se incorporan por referencia en otros documentos de valores. El informe incluye la advertencia estándar sobre declaraciones prospectivas que describe las suposiciones, riesgos e incertidumbres que podrían provocar que los resultados reales difieran de las expectativas. La presentación confirma que las acciones ordinarias de la compañía cotizan en Nasdaq bajo el símbolo ENSC.

Ensysce Biosciences� 2025� 6� 30일로 종료� 회계 분기� 대� 재무 결과� 발표� 보도자료� 제공했다� 보고했습니다. 해당 보도자료� Exhibit 99.1� 첨부되어 있으�, 제출서류에는 회사� Inline XBRL 표지 페이지� 언급되어 있습니다. 보도자료 � 관� 정보� 'furnished'이고 'filed'가 아니�, 따라� 다른 증권 제출서류� 참조� 통합되지 않는다고 명확� 밝힙니다. 보고서에� 실제 결과가 예상� 달라� � 있는 가�, 위험 � 불확실성� 설명하는 표준적인 전향� 진술 경고문이 포함되어 있습니다. 제출서는 회사� 보통주가 Nasdaq에서 ENSC라는 심볼� 거래되고 있음� 확인합니�.

Ensysce Biosciences a déclaré avoir fourni un communiqué de presse annonçant ses résultats financiers pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant qu'Exhibit 99.1 et le dépôt fait également référence à la page de couverture Inline XBRL de la société. Il est précisé que le communiqué et les informations connexes sont 'furnished' et non 'filed', et ne sont donc pas incorporés par renvoi dans d'autres documents relatifs aux titres. Le rapport contient la mise en garde standard relative aux déclarations prospectives, décrivant les hypothèses, les risques et les incertitudes susceptibles d'entraîner un écart entre les résultats réels et les attentes. Le dépôt confirme que les actions ordinaires de la société sont négociées sur le Nasdaq sous le symbole ENSC.

Ensysce Biosciences gab bekannt, dass es eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 beendete Geschäftsquartal übermittelt hat. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und die Einreichung verweist zudem auf die Inline-XBRL-Titelseite des Unternehmens. Es wird klargestellt, dass die Pressemitteilung und die zugehörigen Informationen 'furnished' und nicht 'filed' sind und daher nicht durch Verweis in andere Wertpapierunterlagen einbezogen werden. Der Bericht enthält die übliche Warnung zu zukunftsgerichteten Aussagen, die Annahmen, Risiken und Unsicherheiten beschreibt, die dazu führen können, dass die tatsächlichen Ergebnisse von den Erwartungen abweichen. Die Einreichung bestätigt, dass die Stammaktien des Unternehmens an der Nasdaq unter dem Symbol ENSC gehandelt werden.

false 0001716947 0001716947 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 13, 2025 (August 13, 2025)

 

 

 

Ensysce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38306   82-2755287

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

7946 Ivanhoe Avenue, Suite 201

La Jolla, California

  92037
(Address of principal executive offices)   (Zip Code)

 

(858) 263-4196

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ENSC   The Nasdaq Stock Market LLC

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 13, 2025, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor will they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as will be expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements

 

This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be made directly in this report. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this report, and may include, without limitation, changes in general economic and political conditions, all of which are accordingly subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this report constitute the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this report are subject to a number of factors, risks and uncertainties, some of which are not currently known to the Company, that may cause the Company’s actual results, performance or financial condition to be materially different from the expectations of future results, performance of financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions that the Company believes to be reasonable, there is no assurance that the expected results will be achieved. The Company’s actual results may differ materially from the results discussed in forward-looking statements. Additional information on factors that may cause actual results and the Company’s performance to differ materially is included in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Copies of such filings with the SEC are available publicly on the SEC’s website at www.sec.gov or may be obtained by contacting the Company. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. These forward-looking statements are made only as of the date hereof, and the Company does not undertake any obligations to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

  Description
     
99.1   Press Release, dated August 13, 2025
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 13, 2025 Ensysce Biosciences, Inc.
       
    By: /s/ Lynn Kirkpatrick
    Name:  Dr. Lynn Kirkpatrick
    Title: President and Chief Executive Officer
      (Principal Executive Officer)

 

 

 

FAQ

What did Ensysce (ENSC) disclose in this 8-K?

The company furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025, included as Exhibit 99.1.

Are the financial figures included directly in the 8-K?

No. The 8-K states the press release announces financial results but the filing text provided here does not include numeric financial figures.

Is the press release considered "filed" with the SEC?

No. The filing states the press release and related information are furnished and shall not be deemed to be "filed" or incorporated by reference into other SEC filings.

Does the filing include forward-looking statements?

Yes. The report contains a forward-looking statements section describing assumptions, risks, and uncertainties that could cause actual results to differ from expectations.

On which exchange does Ensysce trade and what is the ticker?

Ensysce's common stock trades on the Nasdaq Stock Market under the symbol ENSC.
Ensysce Biosciences Inc

NASDAQ:ENSC

ENSC Rankings

ENSC Latest News

ENSC Latest SEC Filings

ENSC Stock Data

4.93M
2.27M
0.43%
14.91%
6.72%
Biotechnology
Pharmaceutical Preparations
United States
LA JOLLA